Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 12.
doi: 10.1007/s10557-025-07778-y. Online ahead of print.

Optimizing Lipid-Lowering Strategies Beyond Current Evidence

Mucahit Yetim  1 , Abdülmelik Birgün  1 , Macit Kalçık  2
Affiliations

Optimizing Lipid-Lowering Strategies Beyond Current Evidence

Mucahit Yetim et al. Cardiovasc Drugs Ther. .

Abstract

This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.

Keywords: Cardiovascular outcomes; Coronary artery disease; Ezetimibe; Percutaneous coronary intervention; Statin therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Competing interest: The authors declare no competing interests.

References

    1. Sohn SY, Kim YJ, Doh JH, Cho SW. Moderate-ıntensity atorvastatin and ezetimibe combination therapy versus high-ıntensity atorvastatin in patients with angina pectoris who underwent percutaneous coronary ıntervention. Cardiovasc Drugs Ther. 2025. https://doi.org/10.1007/s10557-025-07729-7 . - DOI - PubMed
    1. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy (RACING trial). Lancet. 2022;400:380–90. - DOI - PubMed
    1. Lee SJ, Joo JH, Park S, et al. Combination lipid-lowering therapy in patients undergoing PCI: generalizability of RACING. J Am Coll Cardiol. 2023;82(5):401–10. - DOI - PubMed
    1. Lin YC, Lai TS, Wu HY, et al. Effects and safety of statin and ezetimibe combination therapy in CKD: a systematic review and meta-analysis. Clin Pharmacol Ther. 2020;108(4):833–43. - DOI - PubMed
    1. Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830–3. - DOI - PubMed

LinkOut - more resources